P50-CA 58207-01/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
1997	2
2001	1
2002	2
2003	1
2004	2
2005	3
2006	1
2013	1
2024	0

1

Development of ligand-targeted liposomes for cancer therapy.

Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC. Noble CO, et al. Expert Opin Ther Targets. 2004 Aug;8(4):335-53. doi: 10.1517/14728222.8.4.335. Expert Opin Ther Targets. 2004. PMID: 15268628 Review.

2

Liposome-based drug delivery in breast cancer treatment.

Park JW. Park JW. Breast Cancer Res. 2002;4(3):95-9. doi: 10.1186/bcr432. Epub 2002 Apr 18. Breast Cancer Res. 2002. PMID: 12052251 Free PMC article. Review.

3

Brain metastases of breast cancer.

Melisko ME, Kunwar S, Prados M, Berger MS, Park JW. Melisko ME, et al. Expert Rev Anticancer Ther. 2005 Apr;5(2):253-68. doi: 10.1586/14737140.5.2.253. Expert Rev Anticancer Ther. 2005. PMID: 15877523 Review.

4

Clinical development of histone deacetylase inhibitors as anticancer agents.

Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Drummond DC, et al. Annu Rev Pharmacol Toxicol. 2005;45:495-528. doi: 10.1146/annurev.pharmtox.45.120403.095825. Annu Rev Pharmacol Toxicol. 2005. PMID: 15822187 Review.

5

Liposome-based approaches to overcome anticancer drug resistance.

Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW. Mamot C, et al. Drug Resist Updat. 2003 Oct;6(5):271-9. doi: 10.1016/s1368-7646(03)00082-7. Drug Resist Updat. 2003. PMID: 14643297 Review.

6

Future directions of liposome- and immunoliposome-based cancer therapeutics.

Park JW, Benz CC, Martin FJ. Park JW, et al. Semin Oncol. 2004 Dec;31(6 Suppl 13):196-205. doi: 10.1053/j.seminoncol.2004.08.009. Semin Oncol. 2004. PMID: 15717745 Review.

7

Immunoliposomes for cancer treatment.

Park JW, Hong K, Kirpotin DB, Papahadjopoulos D, Benz CC. Park JW, et al. Adv Pharmacol. 1997;40:399-435. doi: 10.1016/s1054-3589(08)60146-5. Adv Pharmacol. 1997. PMID: 9217932 Review. No abstract available.

8

Tumor targeting using anti-her2 immunoliposomes.

Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC. Park JW, et al. J Control Release. 2001 Jul 6;74(1-3):95-113. doi: 10.1016/s0168-3659(01)00315-7. J Control Release. 2001. PMID: 11489487

9

Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models.

Weng KC, Hashizume R, Noble CO, Serwer LP, Drummond DC, Kirpotin DB, Kuwabara AM, Chao LX, Chen FF, James CD, Park JW. Weng KC, et al. Nanomedicine (Lond). 2013 Dec;8(12):1913-25. doi: 10.2217/nnm.12.209. Epub 2013 Apr 30. Nanomedicine (Lond). 2013. PMID: 23631502

10

Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. Park JW, et al. Clin Cancer Res. 2002 Apr;8(4):1172-81. Clin Cancer Res. 2002. PMID: 11948130

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Results by year